Immatics (IMTX) Securities (2021 - 2023)

Immatics (IMTX) posted Securities of $64.0 million for Q2 2023, up 1.45% sequentially from $63.1 million in Q1 2023.

Immatics (IMTX) Securities (2021 - 2023) Analysis & Trends

Immatics has reported Securities for 3 years, with the latest figure at $64.0 million in Q2 2023.

Quarterly Securities changed N/A year-over-year to $64.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $64.0 million (changed N/A YoY) and the FY2022 annual result came in at $61.9 million, up 331.65% from the prior year.
Securities grew to $64.0 million in Q2 2023 per IMTX's latest filing, from $63.1 million in the prior quarter.
Over five years, Securities peaked at $64.0 million in Q2 2023 and troughed at $6.1 million in Q1 2022.
A 3-year average of $37.0 million and a median of $37.0 million in 2022 frame the typical range for Securities.
The sharpest annual moves came in 2022 and 2023: Securities soared 332.25% in 2022, then surged 935.21% in 2023.
Over 3 years, Securities stood at $13.9 million in 2021, then jumped by 332.25% to $59.9 million in 2022, then grew by 6.73% to $64.0 million in 2023.
According to Business Quant data, Securities over the past three periods registered $64.0 million, $63.1 million, and $59.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Securities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Immatics	1.27 Bn	719.31 Mn	-	-

Download Data